Assessment of Macular Edema Using HRT Technique
Recruitment status was Not yet recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Age Related Macular Degeneration (ARMD) is the most common cause of irreversible blindness in people of age 50 or older in the western populations. ARMD has two forms, the wet and the dry forms. The wet form is more serious and can lead to irreversible loss of vision. In the wet form of ARMD, new blood vessels grow under the retina. These blood vessels leak blood and fluid and cause the retina and the macula to swell. So the thickness of the macula increases.
One of the key factors in the treatment of wet ARMD is early diagnosis and treatment to prevent complete visual loss. In this research, we are going to use a technique, called the Heidelberg retinal tomograph (HRT) to measure and compare the thickness of the macula in healthy controls and in patients suspected of having ARMD. HRT is a non-invasive imaging system that uses laser to measure the thickness of the macula. This allows us to come up with a quite simple and easy-to-use technique that helps us to diagnose wet ARMD early and treat it before visual acuity is completely lost.
| Condition | Intervention |
|---|---|
|
Age-Related Macular Degeneration |
Device: HRT screening for macula edema |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Single Blind (Outcomes Assessor) Primary Purpose: Diagnostic |
| Official Title: | Assessment of Macular Edema Using HRT Technique |
- Positive predictive value of screening test [ Time Frame: 1 year ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 50 |
| Study Start Date: | April 2008 |
| Estimated Study Completion Date: | July 2009 |
| Estimated Primary Completion Date: | April 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
A
All patients with possible neovascular ARMD are assessed with HRT to determined the positive predictive value of the test
|
Device: HRT screening for macula edema
HRT screening for macula edema at time of initial diagnosis of macular degeneration
|
Show Detailed Description Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- New patients referred by general ophthalmologists to the retina specialist for possible diagnosis of ARMD, exudative formed, will be included in the study.
Exclusion Criteria:
- Significant media opacity
- Other causes of macular edema (ME) (diabetes, vascular occlusions)
- Diabetic patients with retinopathy
Contacts and Locations| Canada, Quebec | |
| MUHC | Not yet recruiting |
| Montreal, Quebec, Canada, H3A 1A1 | |
| Contact: Mila Oh, MDCM, FRCSC (514) 843-1646 milaoh@videotron.ca | |
| Principal Investigator: Mila Oh, MDCM, FRCSC | |
| Principal Investigator: | Mila Oh, MD | McGill University Health Center |
More Information
No publications provided
| Responsible Party: | Mila Oh, MD, MUHC |
| ClinicalTrials.gov Identifier: | NCT00627718 History of Changes |
| Other Study ID Numbers: | BMB 06-029 |
| Study First Received: | February 22, 2008 |
| Last Updated: | February 29, 2008 |
| Health Authority: | Canada: Ethics Review Committee |
Keywords provided by McGill University Health Center:
|
Age-related macular degeneration HRT Macular edema Screening for disease |
Additional relevant MeSH terms:
|
Edema Macular Degeneration Macular Edema Signs and Symptoms |
Retinal Degeneration Retinal Diseases Eye Diseases |
ClinicalTrials.gov processed this record on May 23, 2013